Vaccine produced by German company Bio n Tech.
Germany has begun the approval of the first trial of the Covid-19 vaccine. The trial will be the fourth worldwide of a preventive agent targeting the virus behind the global pandemic. According to reports the trial will be conducted on 200 healthy people aged between 18-55 in the first stage. The second stage of trials will include those in high risk from the disease. Meanwhile, shares in Bio and Tech has suddenly moved up to 40.5%. Also, vaccine trial will be carried out in the United States of America once approval is granted.